Aurobindo Pharma Ltd.'s fourth-quarter profit stayed almost flat in the fourth quarter of financial year 2024-25, thereby missing analysts' estimates.
The Hyderabad-based bulk and generic drugmaker posted a profit of Rs 903.5 crore in the quarter ended March 31, 2025, according to an exchange filing on Monday. That compares with the Rs 1,013-crore consensus estimate of analysts tracked by Bloomberg.
Aurobindo Pharma Q4 FY25 Highlights (Consolidated, YoY)
Revenue up 10.6% to Rs 8,382 crore versus Rs 7,580 crore (Bloomberg estimate: Rs 8,197 crore)
Ebitda up 7% at Rs 1,792 crore versus Rs 1,673 crore (Estimate: Rs 1,827 crore)
Margin narrows to 21.4% versus 22% (Estimate: 22.3%)
Net profit down 0.6% to Rs 903.5 crore versus Rs 909 crore (Estimate Rs 1,013 crore)
The net profit was mainly impacted due to higher interest cost and depreciation expenses. Share of loss of associates and joint ventures of Rs 32 crore versus 12 crore last year, as well as higher tax also impacted net profit
Key Highlights
Revenue from operations with growth across the businesses.
US formulations revenue increased 13.5% to Rs 4,072 crore.
Europe formulations revenue increased 17.2% year on year to Rs 2,147 crore.
Ebitda before R&D stood at Rs 2,202 crore with a margin of 26.3%. R&D, including depreciation, spend was Rs 423 crore, 5% of revenues.
Before the quarterly results were declared, shares of Aurobindo Pharma closed 1.28% lower at Rs 1,181.8 apiece on the NSE, compared to a 0.6% advance in the benchmark Nifty 50.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
